Oak Hill Bio on Phase 3 BEACON trial

Following the recent announcement on the outcome of the phase 3 Aspire trial of GTX-102, Oak Hill Bio has shared a message about their commitment to their ongoing Phase 3 BEACON trial of rugonersen.